Medicare Part D coverage · glipizide · RxCUI 861736
glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
Per the CMS 2026 Part D formulary file, glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet is covered by 5,044 Medicare Part D plans (99.8% of enrollable products), averaging Tier 2.3, with prior authorization required on 0% of covering formularies.
- 99.8%
- Plan coverage
- 5,044
- Plans covering
- T2.3
- Avg tier
- 0%
- Prior auth required
What the CMS Formulary Data Shows for glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
Per the CMS 2026 Part D formulary file, glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet (RxNorm concept RXCUI 861736, generic name glipizide) appears on 326 distinct formulary files spanning 5,044 Medicare Part D plan offerings - 99.8% of enrollable Part D products, near-universal placement. Tier placement ranges from Tier 1 to Tier 6, with a cross-plan average of Tier 2.3.
Real-world access to glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet depends on utilization management as much as tier placement: 0% of covering formularies require prior authorization. 0% require step therapy. 82.8% apply quantity limits.
Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 1,178,840 Part D beneficiaries filled glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet in 2023, with total plan-and-beneficiary spending of $53,145,778 and an average per-beneficiary annual cost of $45.08. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet today.
Coverage Details
- Formularies covering
- 326
- Plans covering
- 5,044
- Coverage rate
- 99.8%
- Tier range
- Tier 1 – Tier 6
- Average tier
- Tier 2, Generic
Restrictions
- Prior authorization required
- 0% of formularies
- Step therapy required
- 0% of formularies
- Quantity limits
- 82.8% of formularies
2023 Medicare Spending
- Beneficiaries
- 1,178,840
- Total spending
- $53,145,778
- Avg per beneficiary
- $45.08
Tier Distribution Across Plans
Standalone Drug Plans (PDP) Covering glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
2 standalone prescription drug plans include this drug.
| Plan | Insurer | Tier | PA | ST | Premium | States |
|---|---|---|---|---|---|---|
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T1 | No | No | $0 | - |
| AARP Medicare Rx Preferred from UHC (PDP) | Unitedhealthcare INS. Co. & UHC INS. Co. OF NY | T1 | No | No | $0 | - |
Medicare Advantage Plans (MA-PD) Covering glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet
98 Medicare Advantage plans with Part D drug coverage include this drug.
| Plan | Insurer | Tier | PA | Premium | States |
|---|---|---|---|---|---|
| UHC Dual Complete IA-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | IA |
| UHC Dual Complete MO-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | MO |
| UHC Dual Complete NE-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | NE |
| UHC Dual Complete KS-S001 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | KS |
| UHC Dual Complete MO-S3 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | MO |
| UHC Dual Complete KS-Q1 (HMO-POS D-SNP) | Unitedhealthcare OF Wisconsin, Inc. | T1 | No | $0 | KS |
| UHC Dual Complete TN-S001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| UHC Dual Complete TN-Y001 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| UHC Dual Complete TN-Y2 (HMO-POS D-SNP) | Unitedhealthcare Plan OF THE River Valley, Inc. | T1 | No | $0 | TN |
| AARP Medicare Advantage from UHC MI-0001 (PPO) | Unitedhealthcare Insurance Company | T1 | No | $0 | MI |
| UHC Dual Complete NM-Y1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete NM-S1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete NM-V1 (PPO D-SNP) | Unitedhealthcare Insurance Company | T1 | No | $0 | NM |
| UHC Dual Complete AZ-S001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T1 | No | $0 | AZ |
| UHC Dual Complete AZ-Y001 (HMO-POS D-SNP) | Arizona Physicians IPA, Inc. | T1 | No | $0 | AZ |
| UHC Dual Complete VA-Y4 (PPO D-SNP) | Care Improvement Plus South Central Insurance Co. | T1 | No | $0 | VA |
| AARP Medicare Advantage from UHC AL-0001 (HMO-POS) | Unitedhealthcare OF THE Midlands, Inc. | T1 | No | $0 | AL |
| AARP Medicare Advantage from UHC CA-0002 (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
| UHC Sharp Medicare Advantage CA-001P (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
| AARP Medicare Advantage from UHC CA-003P (HMO-POS) | UHC OF California | T1 | No | $0 | CA |
Show the next 30 plans
Showing top 50 of 98 plans.
Frequently Asked Questions
Is glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet covered by Medicare Part D?
Yes, glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet is covered by 5,044 Medicare Part D plans (99.8% of all Part D formularies).
What tier is glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet on Medicare Part D plans?
glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet averages Tier 2.3 across Part D plans, ranging from Tier 1 to Tier 6.
Does glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet require prior authorization?
0% of Part D formularies require prior authorization for glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet. Step therapy: 0%. Quantity limits: 82.8%.
How much does Medicare spend on glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet?
In 2023, total Medicare Part D spending on glipizide 2.5 MG / metformin hydrochloride 500 MG Oral Tablet was $53,145,778, covering 1,178,840 beneficiaries. The average spend per beneficiary was $45.08.
Read our methodology - how this data is sourced, computed, and verified.
Nationwide similar Part D drugs
Data-derived peers across the CMS Part D formulary extract: nearest average tier placement and nearest prior-authorization rate. Not therapeutic alternatives or same-generic strengths.
Closest average formulary tier
- 0.5 ML Bordetella pertussis filamentous hemagglutinin vaccine, inactivated 0.01 MG/ML / Bordetella pertussis fimbriae 2/3 vaccine, inactivated 0.01 MG/ML / Bordetella pertussis pertactin vaccine, inactivated 0.006 MG/ML / Bordetella pertussis toxoid vaccine, inactivated 0.02 MG/ML / diphtheria toxoid vaccine, inactivated 30 UNT/ML / tetanus toxoid vaccine, inactivated 10 UNT/ML Injection [Daptacel] T2.3
- 24 HR glipizide 2.5 MG Extended Release Oral Tablet T2.3
- gentamicin 1 MG/ML Topical Cream T2.3
- human-bovine reassortant rotavirus strain G1 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G2 vaccine 1400000 UNT/ML / human-bovine reassortant rotavirus strain G3 vaccine 1100000 UNT/ML / human-bovine reassortant rotavirus strain G4 vaccine 1000000 UNT/ML / human-bovine reassortant rotavirus strain P1A[8] vaccine 1150000 UNT/ML Oral Suspension [RotaTeq] T2.3
- irbesartan 75 MG Oral Tablet T2.3
- morphine sulfate 60 MG Extended Release Oral Tablet T2.3
Similar prior-authorization rate
- metronidazole 10 MG/ML Topical Cream [Noritate] 0% PA
- 24 HR minocycline 40 MG Extended Release Oral Capsule [Emrosi] 0% PA
- buspirone hydrochloride 10 MG Oral Capsule [Bucapsol] 0% PA
- diflunisal 375 MG Oral Tablet [Dolobid] 0% PA
- hydrocortisone 1 MG/ML Oral Solution [Khindivi] 0% PA
- indomethacin 50 MG Rectal Suppository [Indocin] 0% PA